LLY vs QTTB: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
LLY (Eli Lilly) and QTTB (Q32 Bio) share investment themes but are different businesses. The right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme.
LLY vs QTTB: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | LLY | QTTB | What it tells you |
|---|---|---|---|
| Forward P/E | 25.50 | -15.66 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 40.81 | 5.09 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.51 | -0.33 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 84% of range | 65% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 32.90 | 3.58 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how LLY and QTTB affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and QTTB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and QTTB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Eli Lilly (LLY) do?
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.
What does Q32 Bio (QTTB) do?
Q32 Bio Inc. is a clinical-stage biotechnology company focused on alopecia areata (AA) and other autoimmune and inflammatory diseases. Its lead and effectively only clinical program is bempikibart (ADX-914), a fully human monoclonal antibody that blocks the interleukin-7 receptor alpha chain and therefore shuts down signaling from both IL-7 and TSLP, two pathways implicated in the T-cell attack on hair follicles. The company reached the public market by reverse-merging into Homology Medicines in March 2024, which is why the CIK on EDGAR still carries the old FIXX ticker, and it trades on the Nasdaq Capital Market with about 24 employees under CEO Jodie Morrison. Its history since then has been a sequence of narrowing decisions: bempikibart missed in atopic dermatitis (the SIGNAL-AD trial, topline December 2024), the company restructured in February 2025 to focus on AA, and in November 2025 it sold the entire ADX-097 complement program to Akebia Therapeutics. What remains is bempikibart, a preclinical half-life-extended follow-on called ADX-914-XL, and a retained tissue-targeted complement platform (ADX-096 and related molecules) that management describes as under strategic review.
LLY vs QTTB: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
- QTTB drivers: Bempikibart and the path to a registration-directed program; A balance sheet that now outlasts the next trial.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For QTTB, the concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025.
LLY or QTTB: which should you pick?
LLY vs QTTB: the full fundamentals
LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.
QTTB. Figures are approximate, tied to August 2026 and drawn from the Q2 2026 10-Q filed August 5, 2026 and the fiscal 2025 10-K, so check live data before acting on any of them. Two screen-level numbers on QTTB are misleading and worth discarding: the ~5.3x trailing P/E and the ~8.8x price-to-sales both derive from the ~$53.7 million of one-time non-cash collaboration revenue and the ~$29.8 million of 2025 net income it produced, and neither describes an operating business. The number that carries information is enterprise value, roughly ~$276 million once the ~$294 million of pro forma cash is netted against the fully-funded equity value, which is what the market is assigning to bempikibart, the retained complement platform and the Akebia royalty stream combined.
Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); QTTB shows revenue (ttm) ~$53.7 million, all of it recognized in the fourth quarter of 2025 and none of it product revenue: it is the derecognition of a ~$55.0 million refund liability from the terminated Horizon collaboration, settled with Amgen on November 7, 2025 for ~553,695 shares. Revenue in the first half of 2026 was ~$0, loss rate Net loss of ~$8.9 million in Q2 2026 and ~$16.6 million for the first half, on operating expenses of ~$16.8 million (R&D ~$7.5 million, G&A ~$9.4 million); net cash used in operations was ~$9.4 million for the half versus ~$23.1 million a year earlier. Accumulated deficit stands at ~$221.5 million, cash and runway ~$106.3 million of cash and equivalents at June 30, 2026, plus ~$187.6 million net from the July 16 follow-on, for roughly ~$294 million before third-quarter spending. Management states this funds operations through topline Phase 3 results of the planned registration-directed program, and explicitly not through regulatory approval, balance sheet Total assets ~$115.9 million against total liabilities ~$10.0 million and stockholders' equity ~$105.9 million at June 30, 2026, all before the July raise. Debt-free since the ~$6.8 million Silicon Valley Bank venture-debt payoff on June 24, 2026.
The bottom line: LLY vs QTTB
LLY and QTTB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and QTTB exposure against your real portfolio. It is not an investment adviser.
Wondering how LLY or QTTB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Eli Lilly with AI
Connect the broker you already use and ask Walnut's AI how LLY fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between LLY and QTTB?
+
Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Q32 Bio Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is LLY or QTTB the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, LLY or QTTB?
+
On forward P/E (as of August 2026), LLY trades at 25.50x and QTTB at -15.66x, so QTTB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both LLY and QTTB?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of LLY vs QTTB?
+
LLY: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. Competition is intense, especially from Novo Nordisk, and a wave of next-generation oral and combination incretins from multiple companies could pressure share and pricing. Eventual patent expirations and the prospect of compounded or generic competition are long-term overhangs. Drug pricing politics, insurance and reimbursement coverage decisions, and manufacturing or safety setbacks are material risks. Pipeline candidates can fail in trials, and the heavy concentration of the growth story in metabolic medicines raises single-category dependence. QTTB: The concentration risk is total: one unpartnered asset, one indication, and a company that already watched bempikibart fail to earn a path forward in atopic dermatitis before it restructured around AA in February 2025. The July data came from an open-label single-arm trial of 33 patients with no placebo control, and the headline numbers rest on a 25-patient mITT population, so eight of the 33 enrolled patients sit outside the primary analysis and the ITT figures are materially lower (~30.3% versus ~40.0% on SALT20); alopecia areata trials have a long history of placebo responses and spontaneous regrowth that a single-arm design cannot separate out. The economics of a future partnership are encumbered, because bempikibart is in-licensed from Bristol-Myers Squibb under a 2019 agreement that entitles BMS to development and regulatory milestones of ~$32 million to ~$49 million per indication for the first three indications, up to ~$215 million of commercial milestones, royalties from mid-single digits to ~10%, and up to ~60% of any sublicense income, a share that falls only as the program advances. Dilution has been continuous and is not finished: the share count went from ~12.9 million at the end of 2025 to ~29.8 million by August 3, 2026 through a February registered direct, a March ATM with Cantor Fitzgerald, a May private placement at $8.00 and the July follow-on at $18.25, there are ~6.1 million pre-funded warrants outstanding on top of that, and the company states plainly that its cash will not carry any program to regulatory approval. Finally, the listing itself has been fragile before, with a May 19, 2025 Nasdaq notice for falling below the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1) that was only cured on the strength of the Q4 2025 accounting gain and subsequent raises, and a stock that ranged from ~$1.62 to ~$23.57 within twelve months is not one where position sizing is a detail.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LLY or QTTB; figures are approximate and dated (as of August 2026). Verify current data before investing.